Dooradoyle – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dooradoyle – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients https://clinicaltrials.eu/trial/study-comparing-ibrutinib-venetoclax-and-obinutuzumab-for-untreated-chronic-lymphocytic-leukemia-patients/ Wed, 29 Apr 2026 14:27:04 +0000 https://clinicaltrials.eu/trial/study-comparing-ibrutinib-venetoclax-and-obinutuzumab-for-untreated-chronic-lymphocytic-leukemia-patients/ This clinical trial is focused on studying treatments for chronic lymphocytic leukemia (CLL), a type of cancer that affects the blood and bone marrow. The study involves three different treatment approaches. The first treatment is Ibrutinib, which is taken as a monotherapy, meaning it is used alone. The second treatment combines Venetoclax with Obinutuzumab, and the third treatment combines Venetoclax with Ibrutinib. Venetoclax is a medication that helps to kill cancer cells, and Obinutuzumab is an antibody that targets specific cancer cells. The purpose of the study is to compare the effectiveness of these treatments in patients who have not received any prior treatment for their CLL.

Participants in the study will be randomly assigned to one of the three treatment groups. Those receiving Ibrutinib will take it continuously, while those in the other two groups will receive their treatments for a fixed duration. The study will monitor the participants over time to see how well the treatments work in preventing the progression of the disease. This is known as measuring progression-free survival, which means the length of time during and after treatment that the patient lives with the disease without it getting worse.

The study will also look at other outcomes, such as the overall response rate, which measures how well the cancer responds to the treatment, and the duration of response, which is how long the response lasts. Additionally, the study will assess the overall survival of participants, which is the length of time from the start of the study that patients are still alive. By comparing these outcomes, the study aims to determine which treatment approach is most effective for patients with previously untreated chronic lymphocytic leukemia.

]]> Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-enzalutamide-for-patients-with-metastatic-castration-resistant-prostate-cancer/ Wed, 29 Apr 2026 14:24:55 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-enzalutamide-for-patients-with-metastatic-castration-resistant-prostate-cancer/ This clinical trial is focused on studying a type of prostate cancer known as Metastatic Castration-Resistant Prostate Cancer (mCRPC). This is a form of prostate cancer that continues to grow and spread even when the amount of male hormones in the body is reduced to very low levels. The study is testing a combination of two treatments: Pembrolizumab, also known by its code name MK-3475, and Enzalutamide. Pembrolizumab is a medication that helps the immune system fight cancer, while Enzalutamide is used to block the effects of male hormones that can promote cancer growth. The trial will compare the effects of these two drugs together against a combination of a placebo and Enzalutamide.

The purpose of the study is to see if the combination of Pembrolizumab and Enzalutamide can help patients live longer and slow down the progression of the cancer compared to the placebo and Enzalutamide. Participants in the study will receive either the combination of Pembrolizumab and Enzalutamide or the placebo and Enzalutamide. The study will monitor the participants over a period to assess their overall survival and the time it takes for the cancer to progress as seen on medical imaging tests.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effects of the treatment. The study aims to provide valuable information on the effectiveness of combining Pembrolizumab with Enzalutamide in treating this challenging form of prostate cancer. The trial is expected to continue until 2025, providing insights that could lead to improved treatment options for patients with mCRPC.

]]> Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-adt-with-or-without-darolutamide-in-men-with-newly-diagnosed-metastatic-prostate-cancer-and-limited-functional-ability/ Wed, 29 Apr 2026 14:24:21 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-adt-with-or-without-darolutamide-in-men-with-newly-diagnosed-metastatic-prostate-cancer-and-limited-functional-ability/ This clinical trial is focused on studying a type of cancer called prostate cancer, specifically in its advanced stage known as metastatic prostate cancer. This means the cancer has spread from the prostate to other parts of the body. The trial is investigating the effectiveness of a treatment that combines a standard therapy called Androgen Deprivation Therapy (ADT) with a medication named darolutamide, which is also known by its code name BAY 1841788. Darolutamide is a type of drug that blocks certain hormones that can promote cancer growth.

The purpose of the study is to compare the effects of ADT combined with darolutamide against ADT combined with a placebo in men who have not previously received certain other cancer treatments. Participants in the study will be randomly assigned to receive either the combination of ADT and darolutamide or ADT and a placebo. The study will monitor how the cancer progresses over time and assess the overall health and survival of the participants.

Throughout the study, participants will have regular check-ups and tests to track their health and the status of their cancer. The trial aims to provide valuable information on whether adding darolutamide to the standard treatment can help improve outcomes for patients with metastatic prostate cancer who have not been treated with other specific cancer drugs. This research is important for understanding new ways to manage and treat this type of cancer.

]]>